These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study. Miguel-García A, Orero T, Matutes E, Carbonell F, Miguel-Sosa A, Linares M, Tarín F, Herrera M, García-Talavera J, Carbonell-Ramón F. Haematologica; 1998 Apr; 83(4):298-304. PubMed ID: 9592978 [Abstract] [Full Text] [Related]
6. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B, Boccadoro M. Cancer; 2007 Aug 15; 110(4):824-9. PubMed ID: 17594696 [Abstract] [Full Text] [Related]
7. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis]. Scudla V, Budíková M, Fischerová E, Raska I, Vavrdová V. Vnitr Lek; 1991 Apr 15; 37(4):342-51. PubMed ID: 2053304 [Abstract] [Full Text] [Related]
9. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. Molica S, Vitelli G, Mirabelli R, Digiesu G, Giannarelli D, Cuneo A, Ribatti D, Vacca A. Eur J Haematol; 2006 Jan 15; 76(1):51-7. PubMed ID: 16343271 [Abstract] [Full Text] [Related]
10. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M. Bone Marrow Transplant; 1999 Sep 15; 24(5):497-503. PubMed ID: 10482933 [Abstract] [Full Text] [Related]
11. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M. Clin Cancer Res; 2000 Jul 15; 6(7):2702-6. PubMed ID: 10914713 [Abstract] [Full Text] [Related]
14. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma]. Pérez Encinas M, Bello JL, Bendaña A, Rabuñal MJ, González S, Abuín I, Noya M, Cadarso C. Med Clin (Barc); 1998 Jul 11; 111(5):161-7. PubMed ID: 9732831 [Abstract] [Full Text] [Related]
15. Circulating angiogenic cytokines in multiple myeloma and related disorders. Urba ska-Rys H, Wierzbowska A, Robak T. Eur Cytokine Netw; 2003 Jul 11; 14(1):40-51. PubMed ID: 12799213 [Abstract] [Full Text] [Related]
16. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Sezer O, Heider U, Zavrski I, Possinger K. Haematologica; 2001 Aug 11; 86(8):837-43. PubMed ID: 11522540 [Abstract] [Full Text] [Related]
17. [Biochemical and immunological findings of multiple myeloma]. Asaoku H. Nihon Rinsho; 2007 Dec 11; 65(12):2256-60. PubMed ID: 18069270 [Abstract] [Full Text] [Related]
19. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. Domingo-Domènech E, Domingo-Clarós A, Gonzàlez-Barca E, Beneitez D, Alonso E, Romagosa V, De Sanjos S, Petit J, Grañena A, Fernández de Sevilla A. Haematologica; 2002 Oct 11; 87(10):1021-7. PubMed ID: 12368155 [Abstract] [Full Text] [Related]